The lancet. Gastroenterology & hepatology
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study.
Jeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, Anish K Arora, Melina I Manolas, Luis Antonio Diaz, Juan Pablo Arab, Shira Zelber-Sagi, Naim Alkhouri, C Wendy Spearman, Jörn M Schattenberg, Loreta A Kondili, Patrizia Carrieri, Holly F Lofton, Priya Jaisinghani
Published: 202510.1016/S2468-1253(25)00300-0
Abstract
BACKGROUND: An estimated one in three adults is living with metabolic dysfunction-associated steatotic liver disease (MASLD) globally, among whom 20-25% progress to metabolic dysfunction-associated steatohepatitis (MASH). Despite their hepatic and ex…
Preview only. Read the full abstract at the source